SMART-r: Repositorio de seguimiento de sustancias y seguimiento activo de recaídas
Background:
About 1.5 million adults in the US enter alcohol or substance use treatment programs each year. Unfortunately, more than half of patients do not finish their program. For those who start treatment, about 70% return to substance use within weeks or months after starting treatment. To discover why patients drop out of treatment and return to substance use - and what can be done about it - researchers need to learn more about people who use drugs and alcohol.
Objective:
To create a data repository by gathering survey and smartphone data from adults who use drugs and alcohol in order to conduct future research.
Eligibility:
Adults who have used drugs or alcohol in the past and have a Android smartphone. The researchers will recruit targeted demographics at different times throughout the duration of the study period.
Design:
Data will be collected for up to 6 months. All research activities will be online.
Participants will download a smartphone app called TTRU-Curtis AWARE and keep it active on their phone. The app will run in the background and collect participant data, including: screen unlocks, duration of time the screen is on; apps used; words typed (except passwords); duration and time of phone calls; estimated location (exact location is not collected); and movement, such as how many steps are taken in a day. All personally identifying information is automatically removed before the data is stored (including phone numbers, names, or locations described in messages).
Each day, participants will receive a text with a link to a survey. They will answer questions about their mood, behavior, and substance use from the day before. This survey should take less than 5 minutes to complete.
Every 30 days, participants will complete a longer survey. They will answer questions about their personal relationships, risky behaviors, mood, substance use, and feelings. They can skip any questions they do not feel comfortable answering. These surveys should take about 30 minutes to complete.
Participants may opt to allow researchers to access their social media posts.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Description:
This project aims to establish a comprehensive data repository for conducting secondary research, including the analysis of digital phenotype data from individuals who have historically used drugs, including alcohol. Our hypothesis is that digital phenotyping can reveal unique behavioral patterns and risk factors associated with substance use. By collecting data such as smartphone app usage, social media interactions, language data, phone sensor measurements, historical conversational AI data, and wearable device metrics, the TTRU research lab will be able to conduct secondary analyses and uncover insights that could inform prevention and intervention strategies with individuals who use substances.
Objectives
Primary Objective:
The primary objective is to establish the NIDA-IRP Technology and Translational Research Unit (TTRU) Substance Monitoring and Active Relapse Tracking Repository (SMART-r) for collection, storage, and analysis of the human data from individuals who use substances. The secure, high-quality resource of digital, sensor, social media, conversational AI data, self-report, and clinical data (Repository Materials) will be created. Core variables of interest include sensor data, language, and relevant self-report measures. The intention to collect digital phenotyping data is to aid in the efficiency and efficacy of secondary research investigating health outcomes for individuals who use substances by creating a repository of de-identified data.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jessica E Hemmons
- Número de teléfono: Not Listed
- Correo electrónico: jessie.hemmons@nih.gov
Copia de seguridad de contactos de estudio
- Nombre: Brenda L Curtis, Ph.D.
- Número de teléfono: (443) 740-2126
- Correo electrónico: brenda.curtis@nih.gov
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Reclutamiento
- National Institute on Drug Abuse
-
Contacto:
- Jessie Hemmons
- Número de teléfono: Not Listed
- Correo electrónico: smartrstudy@nih.gov
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults who have used drugs or alcohol in the past and have a Android smartphone. The researchers will recruit targeted demographics at different times throughout the duration of the study period.
Descripción
- INCLUSION CRITERIA:
In order to be eligible to participate in the repository, an individual must meet all of the following criteria:
-
Must understand and be willing to complete an online informed consent process.
-
Be an adult aged 18 or older.
-
Self-report alcohol or other drug use within the past 30 days.
-
Have a smartphone as their primary mobile phone.
--For the AWARE app data monitoring procedure, there may be times during this study period where, due to technical or OS limitations, the app is only available to users of certain devices (e.g., Android, iOS). If there is such a limitation, this information will be evaluated during screening. For example, if the AWARE app is not available for iOS, then the screening form may exclude iPhone users for that time period where the limitation exists, if the only procedures offered are daily diary surveys and AWARE data monitoring.
-
Be willing to adhere to the procedures, such as downloading the AWARE app onto their smartphone and keeping it active throughout the data collection period, completing baseline questionnaires, daily diary EMAs, open-ended survey questions with the TTR Chatbot, uploading historical conversational AI data, and/or follow-up surveys.
-
Understand and write in English.
--This exclusion criterion is included because future research on the data collected will include linguistic analysis. all linguistic analyses, we remove rare words (e.g., words must be said by at least 95% of participants)95. Additionally, there are cultural differences across languages and, thus, interpreting language results across more than one language becomes difficult.96 As a result, we must keep analysis limited to a single language (English), since words in other languages will not meet that criteria.
-
Live in the United States.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this repository:
1. Any impairment severe enough to preclude informed consent or valid self-report.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Adults who use substances
Adults 18 years or older who use drugs or alcohol |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
SMARTr data repository
Periodo de tiempo: 20 years
|
The primary objective is to establish the NIDA-IRP Technology and Translational Research Unit (TTRU) Substance Monitoring and Active Relapse Tracking Repository (SMART-r) for collection, storage, and analysis of the human data from individuals who use substances. |
20 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Brenda L Curtis, Ph.D., National Institute on Drug Abuse (NIDA)
Publicaciones y enlaces útiles
Publicaciones Generales
- Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep. 2011 Oct;13(5):398-405. doi: 10.1007/s11920-011-0224-0.
- Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry. 2007 Aug;164(8):1149-59. doi: 10.1176/appi.ajp.2007.05030503.
- Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess. 2009 Dec;21(4):486-97. doi: 10.1037/a0017074.
- Barnett I, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology. 2018 Jul;43(8):1660-1666. doi: 10.1038/s41386-018-0030-z. Epub 2018 Feb 22.
- Lopez-Goni JJ, Fernandez-Montalvo J, Arteaga A. Addiction treatment dropout: exploring patients' characteristics. Am J Addict. 2012 Jan-Feb;21(1):78-85. doi: 10.1111/j.1521-0391.2011.00188.x. Epub 2011 Dec 1.
- Epstein DH, Marrone GF, Heishman SJ, Schmittner J, Preston KL. Tobacco, cocaine, and heroin: Craving and use during daily life. Addict Behav. 2010 Apr;35(4):318-24. doi: 10.1016/j.addbeh.2009.11.003. Epub 2009 Nov 12.
- Lejuez CW, Zvolensky MJ, Daughters SB, Bornovalova MA, Paulson A, Tull MT, Ettinger K, Otto MW. Anxiety sensitivity: a unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behav Res Ther. 2008 Jul;46(7):811-8. doi: 10.1016/j.brat.2008.03.010. Epub 2008 Mar 28.
- Bauer LO. Predicting relapse to alcohol and drug abuse via quantitative electroencephalography. Neuropsychopharmacology. 2001 Sep;25(3):332-40. doi: 10.1016/S0893-133X(01)00236-6.
- Claus RE, Kindleberger LR. Engaging substance abusers after centralized assessment: predictors of treatment entry and dropout. J Psychoactive Drugs. 2002 Jan-Mar;34(1):25-31. doi: 10.1080/02791072.2002.10399933.
- Darke S, Campbell G, Popple G. Retention, early dropout and treatment completion among therapeutic community admissions. Drug Alcohol Rev. 2012 Jan;31(1):64-71. doi: 10.1111/j.1465-3362.2011.00298.x. Epub 2011 Mar 22.
- Evans E, Li L, Hser YI. Client and program factors associated with dropout from court mandated drug treatment. Eval Program Plann. 2009 Aug;32(3):204-12. doi: 10.1016/j.evalprogplan.2008.12.003. Epub 2008 Dec 11.
- Odenwald M, Semrau P. Dropout among patients in qualified alcohol detoxification treatment: the effect of treatment motivation is moderated by Trauma Load. Subst Abuse Treat Prev Policy. 2013 Mar 21;8:14. doi: 10.1186/1747-597X-8-14.
- Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL. Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry. 2009 Jan;66(1):88-94. doi: 10.1001/archgenpsychiatry.2008.509.
- Preston KL, Vahabzadeh M, Schmittner J, Lin JL, Gorelick DA, Epstein DH. Cocaine craving and use during daily life. Psychopharmacology (Berl). 2009 Dec;207(2):291-301. doi: 10.1007/s00213-009-1655-8. Epub 2009 Sep 24.
- McHugh RK. Treatment of co-occurring anxiety disorders and substance use disorders. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):99-111. doi: 10.1097/HRP.0000000000000058.
- Berenz EC, Coffey SF. Treatment of co-occurring posttraumatic stress disorder and substance use disorders. Curr Psychiatry Rep. 2012 Oct;14(5):469-77. doi: 10.1007/s11920-012-0300-0.
- Crosby R, Holtgrave DR, Stall R, Peterson JL, Shouse L. Differences in HIV risk behaviors among black and white men who have sex with men. Sex Transm Dis. 2007 Oct;34(10):744-8. doi: 10.1097/OLQ.0b013e31804f81de.
- Millett GA, Peterson JL, Wolitski RJ, Stall R. Greater risk for HIV infection of black men who have sex with men: a critical literature review. Am J Public Health. 2006 Jun;96(6):1007-19. doi: 10.2105/AJPH.2005.066720. Epub 2006 May 2.
- Levy ME, Wilton L, Phillips G 2nd, Glick SN, Kuo I, Brewer RA, Elliott A, Watson C, Magnus M. Understanding structural barriers to accessing HIV testing and prevention services among black men who have sex with men (BMSM) in the United States. AIDS Behav. 2014 May;18(5):972-96. doi: 10.1007/s10461-014-0719-x.
- Shuper PA, Joharchi N, Bogoch II, Loutfy M, Crouzat F, El-Helou P, Knox DC, Woodward K, Rehm J. Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men. BMC Public Health. 2020 Nov 25;20(1):1782. doi: 10.1186/s12889-020-09883-z.
- Gebru NM, Benvenuti MC, Rowland BHP, Kalkat M, Chauca PG, Leeman RF. Relationships among Substance Use, Sociodemographics, Pre-Exposure Prophylaxis (PrEP) Awareness and Related Attitudes among Young Adult Men Who Have Sex with Men. Subst Use Misuse. 2022;57(5):786-798. doi: 10.1080/10826084.2022.2040030. Epub 2022 Feb 21.
- Crozier ME, Farokhnia M, Persky S, Leggio L, Curtis B. Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving. BMJ Ment Health. 2023 Nov 22;26(1):e300852. doi: 10.1136/bmjment-2023-300852.
- Torous J, Onnela JP, Keshavan M. New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices. Transl Psychiatry. 2017 Mar 7;7(3):e1053. doi: 10.1038/tp.2017.25.
- Jain SH, Powers BW, Hawkins JB, Brownstein JS. The digital phenotype. Nat Biotechnol. 2015 May;33(5):462-3. doi: 10.1038/nbt.3223. No abstract available.
- Boukhechba M, Chow P, Fua K, Teachman BA, Barnes LE. Predicting Social Anxiety From Global Positioning System Traces of College Students: Feasibility Study. JMIR Ment Health. 2018 Jul 4;5(3):e10101. doi: 10.2196/10101.
- Giorgi S, Yaden DB, Eichstaedt JC, Ungar LH, Schwartz HA, Kwarteng A, Curtis B. Predicting U.S. county opioid poisoning mortality from multi-modal social media and psychological self-report data. Sci Rep. 2023 Jun 3;13(1):9027. doi: 10.1038/s41598-023-34468-2.
- Son Y, Clouston SAP, Kotov R, Eichstaedt JC, Bromet EJ, Luft BJ, Schwartz HA. World Trade Center responders in their own words: predicting PTSD symptom trajectories with AI-based language analyses of interviews. Psychol Med. 2023 Feb;53(3):918-926. doi: 10.1017/S0033291721002294. Epub 2021 Jun 22.
- Meyerhoff J, Liu T, Stamatis CA, Liu T, Wang H, Meng Y, Curtis B, Karr CJ, Sherman G, Ungar LH, Mohr DC. Analyzing text message linguistic features: Do people with depression communicate differently with their close and non-close contacts? Behav Res Ther. 2023 Jul;166:104342. doi: 10.1016/j.brat.2023.104342. Epub 2023 May 27.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 10002094
- 002094-DA
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Only aggregated data will be made available upon request.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .